Revolution Medicines (RVMD) Gains from Sales and Divestitures (2020 - 2026)

Revolution Medicines' Gains from Sales and Divestitures history runs 7 years deep, the most recent figure standing at $367871.0 for Q1 2026.

• In Q1 2026, Gains from Sales and Divestitures rose 35.48% year-over-year to $367871.0; the TTM figure through Mar 2026 stood at $367871.0 (up 35.48% YoY), while the FY2025 annual figure was $1.3 million, up 33.43% from the prior year.
• Gains from Sales and Divestitures was $367871.0 for Q1 2026 at Revolution Medicines, down from $1.3 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $1.3 million in Q4 2025 to a low of $26931.0 in Q1 2022.
• Historically, Gains from Sales and Divestitures has averaged $466786.6 across 5 years, with a median of $367871.0 in 2026.
• The sharpest annual moves came in 2022 and 2025: Gains from Sales and Divestitures surged 1397.83% in 2022, then jumped 33.43% in 2025.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $278848.0 in 2022, then surged by 106.91% to $576974.0 in 2023, then soared by 75.27% to $1.0 million in 2024, then jumped by 33.43% to $1.3 million in 2025, then plunged by 72.74% to $367871.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $367871.0 (Q1 2026), $1.3 million (Q4 2025), and $978467.0 (Q3 2025), per Business Quant data.